George Yeh joined TLC in 2002 as President and leads the Company’s operations. George is responsible for strategic planning of the Company’s drug programs, business operations, corporate development, product licensing, and management of corporate funding. With George’s ability to organize and lead the capable team, TLC flourished into one of the fastest‐growing drug delivery companies in Asia in a relatively short period of time. TLC was named one of the Top 100 Private Companies by Red Herring Asia in 2006 and shortlisted for Red Herring Global in 2007. George received the “Outstanding Young Innovator Award” in 2008 for his contribution to the biotechnology industry in Taiwan. Under George’s guidance, the TLC team worked collectively to become listed on the Taipei Exchange in 2012, and TLC has been ranked in the Top 5% in Corporate Governance Evaluations every year since then. TLC then became the first Taiwan-based biotech company to be listed on Nasdaq in 2018.